FDA opens investigational application for Corlux orphan drug

WASHINGTON Corcept Therapeutics has received notification from the Food and Drug Administration that they have opened an investigational application for its drug Corlux.

Corlux is used to treat Cushing’s syndrome, which is a disorder caused by prolonged exposure of the body’s tissues to high levels of the hormone cortisol.

Back in July, the FDA gave Corlux an orphan drug designation and said that “a single study may provide a reasonable basis” for a new drug application, according to the company.